Products

What will AGI do for Brefonalol?

This classification denotes a vasodilating agent and adrenergic antagonist with the molecular formula C22H28N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DVO6SSG9S3, chemically known as (+-)-6-(2-((1,1-dimethyl-3-phenylpropyl)amino)-1-hydroxyethyl)-3,4-dihydrocarbostyril but generally known as brefonalol, which bears US NIH Compound Identifier 65880. European Medicines Agency schedules Brefonalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05883MIG. The term BREFONALOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). BREFONALOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule brefonalol under HS 29337900 and SITC 51561. As of Q4 2014, BREFONALOL remains the US FDA Preferred Term for this commodity. Brefonalol bears US NLM identifiers UMLS ID C2347204 and NCI Concept Code C72653. SMILES: OC(CNC(CCC1CCCCC1)(C)C)C1CC2CCC(=O)NC2CC1.

How AGI delivers it

Four ways AGI delivers for Brefonalol

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Brefonalol, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Brefonalol, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Brefonalol connects

measured by

  • Chiral Enantiomeric Excessmodel
  • Compound Puritymodel